On October 28, 2021, Sanofi reported robust financial third quarter results for 2021. The pharmaceutical company reported double-digit sales growth of 10.1% during the third quarter, which predominantly were driven by the notable performance of Dupixent, record sales of Vaccines and continued strong business momentum in Consumer Healthcare. Notably, these results are in line with the direction provided by the company in the previous quarter. In addition, exchange rate movements had a neutral effect in the third quarter, the negative impact of the U.S. dollar, Japanese yen and Turkish lira was offset by the increase of the Chinese Yuan and some other currencies. In specific terms, revenue in the first nine months of 2021 amounted to €27.8 billion on a reported basis. Click here to access the report